Kevin C. Miller

Oncology

399 Revolution Dr
Suite 580
Somerville, MA 02145

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 23, 2026

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Journal: Blood cancer journal

Published: November 22, 2025

First-line Therapy in Newly Diagnosed Multiple Myeloma.

First-line Therapy in Newly Diagnosed Multiple Myeloma.

Journal: Blood cancer discovery

Published: October 22, 2025

Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Journal: Blood cancer journal

Published: October 13, 2025

IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.

IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.

Journal: Blood advances

Published: September 24, 2025

IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.

IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.

Journal: Blood advances

Published: September 24, 2025

Incorporating the Next Generation of Immunotherapies Into the Treatment of Multiple Myeloma.

Incorporating the Next Generation of Immunotherapies Into the Treatment of Multiple Myeloma.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 16, 2025

NAVIGATING CARE: THE GI NURSE'S ROLE IN MANAGING OLDER ADULT PATIENTS WITH DELIRIUM.

NAVIGATING CARE: THE GI NURSE'S ROLE IN MANAGING OLDER ADULT PATIENTS WITH DELIRIUM.

Journal: Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates

Published: September 02, 2025

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma.

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma.

Journal: Blood cancer journal

Published: June 21, 2025

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Journal: Blood cancer journal

Published: May 04, 2025

Recycling is "bad to the bone" in patients with myeloma.

Recycling is "bad to the bone" in patients with myeloma.

Journal: Blood

Published: April 24, 2025

Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.

Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.

Journal: Blood advances

Published: February 10, 2025

Showing 1-12 of 36

Last Updated: 09/26/2026